Nitrate Vasodilator Drug Class List

Drugs in Drug Class: Nitrate Vasodilator

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	RECTIV	nitroglycerin	OINTMENT;INTRA-ANAL	021359-001	Jun 21, 2011		DISCN	Yes	No
Viatris	NITROSTAT	nitroglycerin	TABLET;SUBLINGUAL	021134-001	May 1, 2000	AB	RX	Yes	No
Viatris	NITROSTAT	nitroglycerin	TABLET;SUBLINGUAL	021134-002	May 1, 2000	AB	RX	Yes	No
Viatris	NITROSTAT	nitroglycerin	TABLET;SUBLINGUAL	021134-003	May 1, 2000	AB	RX	Yes	Yes
Pohl Boskamp	NITROLINGUAL PUMPSPRAY	nitroglycerin	SPRAY, METERED;SUBLINGUAL	018705-002	Jan 10, 1997	AB	RX	Yes	Yes			Y
Pohl Boskamp	NITROLINGUAL	nitroglycerin	AEROSOL;SUBLINGUAL	018705-001	Oct 31, 1985		DISCN	No	No

Last updated: July 6, 2026

Nitrate Vasodilator Market Dynamics and Patent Landscape: Key Patents, Exclusivity Timelines, and Generic/Biosimilar Risk

Nitrate vasodilators remain dominated by legacy small-molecule actives with long patent histories and, in most markets, limited scope for new patent exclusivity on core chemistry. Competitive dynamics therefore hinge on (1) formulation and delivery-system patents (controlled-release oral, transdermal, buccal/sublingual), (2) combination products (often with antihypertensives), (3) device and patch technologies, and (4) regulatory “regulatory exclusivity” rather than active-ingredient composition-of-matter. For most major nitrate actives, generic entry is the baseline scenario; the remaining profit pool tracks to patent-protected product presentations and to originator-sponsored line extensions.

---

What patents protect nitrate vasodilators (nitroglycerin, isosorbide dinitrate, isosorbide mononitrate) by formulation and delivery system?

Featured snippet answer: Patent protection in nitrate vasodilators typically concentrates in controlled-release, transdermal patch/adhesive, and sublingual/buccal delivery technologies rather than in the underlying nitrate chemistry.

Core actives and typical patent-holder patterns

Nitrate vasodilators in commercial use include:

• Nitroglycerin (sublingual tablets/sprays, topical ointments, transdermal systems, extended-release oral)
• Isosorbide dinitrate (ISDN) (immediate-release oral, controlled-release oral)
• Isosorbide mononitrate (ISMN) (once-daily extended-release oral tablets)

In practice, many originator composition-of-matter and method patents for these actives have expired in major jurisdictions. Current “live” patent estates tend to be product-specific and territory-specific, with remaining litigation risk concentrated around:

• Rate-controlled release profiles
• Coating layers and matrix systems
• Patch construction, backing/adhesive compositions, and metering mechanisms
• Stability and bioavailability improvements
• Specific dosing regimens tied to clinical labeling

Delivery-system patent clusters that drive residual exclusivity

Common areas where nitrate product patents still persist:

1. Controlled-release oral dosage forms
   • Matrix or multilayer tablets
   • Osmotic pump-like controlled release designs (where applicable)
   • Coating and dissolution-profile patents designed to sustain plasma levels and reduce headache incidence
2. Transdermal systems
   • Adhesive formulation patents
   • Membrane and metering layer structures
   • Patch activation and skin-contact design
3. Sublingual/buccal fast-acting products
   • Particle engineering, taste-masking, and wetting agents
   • Film or tablet composition enabling consistent absorption

How many patents cover a typical nitrate product line?

Patent families for a single branded product line often include:

• 5 to 15 related formulation or device patents (per jurisdiction and continuation strategy)
• 1 to 5 method-of-use/regimen patents (less common for older nitrates than for newer drugs, but still used for line extensions)

---

When do nitrate vasodilators lose exclusivity (composition-of-matter vs product-use patents)?

Featured snippet answer: For most established nitrate actives, composition-of-matter exclusivity is already expired in leading markets; exclusivity risk today is driven by late-life formulation and delivery-system patents and by regulatory exclusivities tied to specific product approvals.

Why “generic already exists” is the default

Nitrate vasodilators are older generics-friendly molecules. For business planning:

• Active ingredient generic availability tends to be mature
• Remaining barriers are product-specific (Orange Book listed patents for branded presentations, or patent-protected manufacturing processes)

Typical timeline mechanics

Exclusivity can come from three channels:

1. Patent term
   • Utility patents for formulations and delivery systems
   • Sometimes pediatric or PTA extensions in some cases
2. Regulatory data exclusivity
   • Often limited relevance for older actives unless a new NDA is involved
3. Orphan/other special designations
   • Rare for classic nitrate indications in many markets

Practical consequence: Market share defense often continues through authorized generics, “drop-in” line extensions, and reformulations rather than through broad chemistry exclusivity.

---

What is the Orange Book status of nitrate vasodilators (nitroglycerin, ISDN, ISMN) and which patents remain listed?

Featured snippet answer: Orange Book listings for nitrate vasodilators generally show a mix of expired active-ingredient patents and still-listed product formulation or method patents, especially for controlled-release oral and transdermal systems.

Where patent listings concentrate

Across many nitrate product Orange Book records:

• “Drug substance” entries are frequently obsolete by the time the product matures.
• “Drug product” entries (and some method-of-use patents) tend to be the ones that keep legal leverage.

Commercially relevant patent list interpretation

For a generic challenger, the key decision is whether there are still-listed patents that cover:

• The exact dosage form (tablet vs patch vs sublingual)
• The exact release profile (extended-release vs immediate)
• The exact route (oral vs transdermal vs buccal)

If the branded product’s formulation patents remain listed, generic approval may require:

• Paragraph IV ANDA certification against those patents, or
• Labeling carve-outs and/or design-around strategies that avoid infringement

---

How strong is the patent estate for nitrate transdermal patches vs oral controlled-release tablets?

Featured snippet answer: Transdermal nitrate patches often have stronger residual patent leverage because patch performance depends on multi-component adhesive and metering architecture that is easier to patent than core chemistry. Oral controlled-release tablets usually have substantial formulation IP as well, but the space can be more design-around friendly through dissolution-profile matching.

Transdermal patches: typical legal leverage points

• Adhesive composition (contact, absorption, skin compatibility)
• Drug reservoir and membrane structures
• Patch construction and manufacturing steps that affect dosing uniformity

Oral controlled-release: typical legal leverage points

• Matrix/coating systems controlling dissolution rate
• Multilayer designs that produce time-dependent plasma profiles
• Stability and bioavailability improvements

---

Which generic entry risks exist for nitrate vasodilators and what triggers Paragraph IV challenges?

Featured snippet answer: Paragraph IV challenges are typically triggered when (1) Orange Book listed patents still cover the branded dosage form, and (2) the challenger believes it can launch via a design-around or expects a favorable validity/unenforceability position.

Common generic entry patterns

1. ANDA for controlled-release oral products
   • Risk centers on dissolution and in vivo bioequivalence comparability
   • If listed formulation patents claim specific release-control elements, challengers may file Paragraph IV
2. ANDA for transdermal systems
   • Risk centers on patch architecture and adhesives
   • Challengers can pursue noninfringing architectures, but if claims are broad, litigation risk increases

Business drivers of challenger timing

• When patent terms approach expiration (strategic filing ahead of launch windows)
• When originators introduce line extensions that delay generic substitution
• When settlement patterns make “early resolve” cheaper than prolonged litigation

---

What nitrate patent litigation affects generic launch dates (and how do settlements work)?

Featured snippet answer: Litigation in nitrate vasodilators usually clusters around dosage-form patents for controlled-release tablets and transdermal systems. Settlement structures commonly involve launch-date carve-outs tied to patent expiry or to earlier “design-around” noninfringement.

Settlement mechanics seen in small-molecule generics

While each case is fact-specific, typical settlement patterns include:

• Agreed earlier launch of a generic in exchange for dismissal or covenant not to sue
• Delayed launch until a specific patent expires
• Design-around commitments by the generic that change formulation/process enough to avoid infringement

Impact on generic entry risk

For pipeline planning, the key litigation question is not whether litigation occurs, but:

• Whether the settlement grants a clear launch date for the specific dosage form at issue
• Whether additional later-expiring patents remain listed, affecting “last patent standing” dynamics

---

How does nitrate vasodilator use split across indications and how does that influence patent strategy (method-of-use claims)?

Featured snippet answer: Indications for nitrates typically center on angina prophylaxis and acute relief, which limits how often method-of-use claims can remain meaningful. Where method claims persist, they typically support specific dosing regimens for prevention strategies or label refinements.

Method-of-use claim relevance

• Older standard-of-care regimens often face patentability constraints.
• Originators still pursue method claims when they can tie to:
  • Specific dosing schedules (including titration approaches)
  • Specific patient subpopulations
  • Reduction strategies like avoiding tolerance with dosing breaks (where supported in labeling)

For generic planning, method-of-use patents can matter if label language would induce infringement or if the challenger seeks to copy a dosing regimen closely.

---

What are the major competitive dynamics in nitrate vasodilators by delivery format (sublingual vs extended-release oral vs transdermal)?

Featured snippet answer: Competitive intensity is highest in immediate and generic-ready formats; differentiation persists in sustained-release oral and transdermal systems where formulation patents and performance-driven switching matter.

Sublingual fast relief

• Brand differentiation historically hinged on stability, dissolution, and onset consistency.
• Today, many markets are generic-dense; switching depends on patient preference, coverage, and device/patient education.

Extended-release oral (ISDN/ISMN)

• Differentiation concentrates on dissolution profile matching and tolerability.
• Once-daily convenience can maintain premium pricing in patent-protected windows.

Transdermal patches

• Switching is influenced by skin tolerability, adhesion, dosing continuity, and dosing uniformity.
• Delivery-system patent estates can preserve margins longer than for immediate-release.

---

How do combination products affect the nitrate patent landscape and FDA approval pathways?

Featured snippet answer: Combination products shift patent attention toward combination formulations, co-crystals if relevant, and fixed-dose regimens, while regulatory pathways remain largely generic-compatible unless a specific combination patent remains listed.

Combination product effects

• New combinations can receive new patent coverage around fixed-dose dosage forms
• Even when the nitrate active is generic, the combination dosage form can be patent-protected for longer

Regulatory planning hinges on:

• Whether the combination is an ANDA-able formulation
• Whether listed patents cover the combination product specifically

---

Which companies hold the most relevant nitrate vasodilator IP in major markets and how do their strategies differ?

Featured snippet answer: In established nitrate categories, the IP “center of gravity” is typically with originator brands controlling product development and line extensions for controlled-release and transdermal presentations, while multiple generic manufacturers maintain ANDA capability for older formulations.

Originator strategy

• Extend brand franchises via:
  • Controlled-release improvements
  • Patch architecture innovations
  • Lifecycle management through reformulation and line extension

Generic strategy

• Target:
  • High-volume strengths and the most substitutable dosage forms
  • Filings timed to remaining Orange Book patents
  • Design-around formulations to avoid infringement claims, especially where patch claims are broad

---

What is the FDA regulatory status of nitrate vasodilators (NDA vs ANDA dominance) and what does it mean for patent timing?

Featured snippet answer: The nitrate vasodilator category largely operates under ANDA-heavy market structure for older actives. Patent timing for challengers is therefore driven by the last remaining listed product patents and by patent settlements that constrain launch.

Regulatory mechanics relevant to exclusivity

• The challenger’s “real” gating factor is often not data exclusivity but patent listings that must be addressed via certifications.
• For an incumbent brand, regulatory events can “re-list” patents if the brand is modified through supplemental applications that trigger Orange Book patent listings.

---

Revenue exposure: which nitrate vasodilator product types carry the highest patent-driven economic risk?

Featured snippet answer: The highest patent-driven economic exposure sits in branded controlled-release oral and transdermal products where the remaining patent estate can materially delay full generic substitution.

Exposure logic

• Higher remaining patent leverage implies:
  • Longer brand pricing power
  • Greater relevance of Paragraph IV disputes at the product level
• Immediate-release forms have lower exposure because the market tends to be generic-dominant and less dependent on still-asserted formulation patents.

---

What formulation and manufacturing/IP barriers block nitrate generic entry?

Featured snippet answer: The barriers are primarily formulation-specific and process-specific: dissolution profile matching for controlled-release and patch construction and metering layer design for transdermals.

Barriers by format

• Controlled-release oral
  • Release kinetics matching without infringing dissolution-control claims
  • Stability of coating/matrix over shelf life
• Transdermal
  • Adhesive selection and patch architecture that meets dose uniformity
  • Avoiding claims that cover specific reservoir/metering structures
• Sublingual/buccal
  • Particle size, wetting, and taste masking affecting performance
  • Less often the core claim drivers today versus patch and controlled-release

---

Key Takeaways

• Patent exclusivity in nitrate vasodilators is concentrated in product formulation and delivery-system patents, not in the underlying nitrate chemistry, which is largely mature.
• Generic entry risk depends on Orange Book listed patents tied to the specific dosage form and release profile, with transdermal and controlled-release oral products carrying higher residual legal leverage.
• Litigation and settlements typically resolve around dosage-form infringement and produce launch dates aligned to patent expiry or design-around acceptance.
• Market dynamics track delivery format: immediate relief is heavily generic-dense, while sustained-release oral and transdermal remain where brand economics can persist through line extensions and formulation IP.

---

FAQs

1. Which nitrate vasodilator strengths are most commonly targeted for generic substitution in extended-release products?
2. Do transdermal nitrate generic products need full claim-by-claim design-around to clear litigation risk?
3. How do supplemental NDA approvals for nitrate patches or controlled-release tablets change Orange Book patent listings?
4. What dissolution-profile endpoints are most used to assess similarity for controlled-release isosorbide mononitrate generics?
5. How do covenants-not-to-sue in nitrate patent settlements typically affect subsequent ANDA amendments and label language?

---

References (APA)

1. FDA. (n.d.). Drugs@FDA: Drug Product Database. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/ob/